Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

Return to program book search

Session Information

FRM F042 - Merkel Cell Carcinoma: Diagnosis, Management & Controversies

Open admission to eligible categories, no tuition or ticket


Date: Saturday, March 22

CME Credits: 2.00

Location: Room 201

Time: 10:00 AM - 12:00 PM

Director: Christopher K. Bichakjian, MD, FAAD - Handout

  • Klaus J. Busam, MD
  • Marcus L. Frohm, MD
  • Paul Nghiem, MD, PhD, FAAD
  • Monique Verhaegen

Learning Objectives:
Following this course, the attendee should be able to:

  • Identify areas of consensus and controversy regarding the clinical, pathologic, and prognostic characteristics of Merkel cell carcinoma.
  • Utilize recent developments in the clinical management of Merkel cell carcinoma, including sentinel lymph node biopsy and adjuvant therapy, to guide the multidisciplinary care of this malignancy.
  • Analyze recent scientific data on the pathogenesis of Merkel cell carcinoma in relation to outcomes and emerging therapies.

Merkel cell carcinoma (MCC) is a polyomavirus-associated skin cancer with a higher disease-specific mortality than melanoma and an increasing incidence of ~1600 cases/year in the US. Clinical management is challenging due to the lack of evidence-based data and wide-ranging treatment recommendations in the literature. Multidisciplinary care is frequently indicated and strongly encouraged. This session will focus on current concepts in the diagnosis and management of MCC and highlight areas of consensus and controversy. Recent scientific advances in the pathogenesis of MCC and the potential future therapeutic implications will be reviewed.


Saturday, March 22
10:00 AMIntroduction / Dr. Bichakjian
10:05 AMPathologic Diagnosis and Features, and Prognostic Implications / Dr. Busam
10:25 AMTreatment of the Primary Tumor Site / Dr. Frohm
10:45 AMMerkel Cell Polyomavirus, Immunity, and Targeted Therapy / Dr. Nghiem
11:05 AMContemporary Management and Outcomes / Dr. Bichakjian
11:25 AMBench to Bedside: Targeting the Apoptotic Machinery / Dr. Verhaegen
11:45 AMQuestions and Answers / All faculty